

## Supplementary material

*Kaczmarek K, Kuniewicz M, Romanek J, et al. Real world experience with cryoballoon ablation for the treatment of atrial fibrillation in Poland: 24-month outcomes from the Cryo Global Registry. Pol Heart J. 2024.*

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

**Table S1.** Patient baseline characteristics


<b>Subject characteristic</b>	<b>Patients undergoing cryoballoon ablation in Poland (n = 178)</b>
Sex (female), n (%)	52 (29.2)
Age, years, mean (SD)	60 (10)
Body mass index, kg/m <sup>2</sup> , mean (SD)	30 (4)
CHA <sub>2</sub> DS <sub>2</sub> -VASc Score, median (Q1–Q3)	2.0 (1.0–3.0)
Clinical classification of atrial fibrillation	
Paroxysmal atrial fibrillation, n (%)	144 (80.9)
Persistent atrial fibrillation, n (%)	34 (19.1)
Time from first atrial fibrillation diagnosis, years, median (Q1-Q3)	2.2 (1.0–4.2)
Number of failed antiarrhythmic drugs, mean (SD)	1.1 (0.7)
Prior flutter ablation, n (%)	16 (9.0)
Prior ablation for atrial fibrillation, n (%)	3 (1.7)
Left atrial diameter, mm, mean (SD)	44 (6)
Left ventricular ejection fraction, %; mean (SD)	55 (11)
Hypertension, n (%)	129 (72.5)
Heart failure, n (%)	63 (35.4)
Baseline New York Heart Association Functional Class	
Class I, n (%)	22 (12.4)
Class II, n (%)	31 (17.4)
Class III, n (%)	10 (5.6)
Class IV, n (%)	0 (0.0)
Prior myocardial infarction, n (%)	17 (9.6)
Prior stroke/transient ischemic attack, n (%)	16 (9.0)
Coronary artery disease, n (%)	27 (15.2)
Diabetes, n (%)	46 (25.8)
Sleep apnea, n (%)	21 (11.8)

CHA<sub>2</sub>DS<sub>2</sub>-VASc score is a composite index evaluating stroke risk in a patient. Variables which increase the score are congestive heart failure, hypertension, age ≥65 years, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, and female sex


**Table S2.** Prescription of anti-arrhythmic drugs (AAD) per center

	<b>AAD at baseline</b>	<b>AAD at discharge</b>	<b>AAD at month 12</b>	<b>AAD at month 24</b>
Site 1	81 (81.8%)	82 (82.8%)	62 (63.9%)	65 (69.2%)
Site 2	46 (93.9%)	27 (55.1%)	18 (37.5%)	20 (41.7%)
Site 3	10 (33.3%)	8 (26.7%)	7 (23.3%)	11 (37.9%)
<b>Total</b>	<b>137 (77.0%)</b>	<b>117 (65.7%)</b>	<b>87 (49.7%)</b>	<b>96 (56.1%)</b>

Data on AAD prescription was available for 171 of 178 patients



**Figure S1.** Frequency of arrhythmia monitoring



	Number at Risk								
	0	3	6	9	12	15	18	21	24
Multiple Freeze	101	100	93	92	82	74	72	71	70
Single Freeze	77	77	70	65	62	58	56	53	51

	Number of subjects	Number of freeze per vein
Single freeze cohort	77 (43.3%)	1
Multiple freeze cohort	101 (56.7%)	Median (Q1-Q3): 1 (1-2)

**Figure S2.** Effect of single freeze attitude on efficacy